Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

fludarabine phosphate 6Cyclophosphamide 6fludarabine 4Whole-Body Irradiation 4Mycophenolic Acid 4tagraxofusp 3Thiotepa 3Methotrexate 3Cyclosporine 3venetoclax 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Dexamethasone 2Cytarabine 2Cyclosporins 2Calcium Dobesilate 2Azacitidine 2merphos 1lorvotuzumab mertansine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Vincristine 1Sirolimus 1Salvia hispanica seed extract 1Rituximab 1Ranitidine 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blastic Plasmacytoid Dendritic Cell Neoplasm × lorvotuzumab mertansine × Other hematologic neoplasm × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡